- EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
-
Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, Park K, Ahn MJ
- KMID: 2507954
- Cancer Res Treat.
- 2020 Oct;52(4):1288-1290.
- doi: 10.4143/crt.2020.278
The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option,... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study
-
Ku BM, Park S, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Choi YL, Ahn MJ
- KMID: 2538088
- Precis Future Med.
- 2022 Dec;6(4):233-242.
- doi: 10.23838/pfm.2022.00058
Purpose: Mesenchymal-epithelial transition tyrosine kinase receptor (MET) amplification is one of the common acquired resistance mechanisms to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). To evaluate the usefulness... -
- CITED
-
- Close
- SHARE
-
- Close
- Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
-
Lee MY, Ku BM, Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Park K, Oh YL, Hong M, Jeong HS, Son YI, Baek CH, Ahn MJ
- KMID: 2394810
- Cancer Res Treat.
- 2017 Oct;49(4):906-914.
- doi: 10.4143/crt.2016.424
PURPOSE: Papillary thyroid carcinomas (PTCs) frequently involve genetic alterations. The objective of this study was to investigate genetic alterations and further explore the relationships between these genetic alterations and clinicopathological... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
-
Kim KH, Hur JY, Koh J, Cho J, Ku BM, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC
- KMID: 2511879
- Immune Netw.
- 2020 Dec;20(6):e48.
- doi: 10.4110/in.2020.20.e48
Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration of tumor growth after treatment with anti-PD-1/PD-L1 Abs. However, the immunological characteristics have not been fully elucidated in... -
- CITED
-
- Close
- SHARE
-
- Close
- Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
-
Ku BM, Heo MH, Kim JH, Cho BC, Cho EK, Min YJ, Lee KH, Sun JM, Lee SH, Ahn JS, Park K, Kim TJ, Lee HY, Kim H, Lee KJ, Ahn MJ
- KMID: 2412926
- J Pathol Transl Med.
- 2018 May;52(3):148-156.
- doi: 10.4132/jptm.2018.03.12
BACKGROUND: Non-small cell lung cancer (NSCLC) is a common type of cancer with poor prognosis. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in NSCLC might... -
- CITED
-
- Close
- SHARE
-
- Close
